# Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

> **NCT04596319** · PHASE1,PHASE2 · COMPLETED · sponsor: **Armata Pharmaceuticals, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Cystic Fibrosis
- Pseudomonas Aeruginosa
- Pseudomonas
- Lung Infection
- Lung Infection Pseudomonal

## Interventions

- **BIOLOGICAL:** AP-PA02
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04596319
- **Lead sponsor:** Armata Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04596319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04596319, "Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04596319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*